^
    over2years
    Landscape of EGFR Extracellular Domain Mutations in Advanced Non Small Cell Lung Carcinoma (IASLC-WCLC 2022)
    This analysis describes the largest EGFR ECD mutational landscape of advanced NSCLC patients detected via ctDNA. EGFR ECD mutations in NSCLC do not appear to be mutually exclusive with other oncogenic driver mutations, and further evaluation of biological and clinical relevance is warranted.
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • KRAS Q61H • EGFR E114K • ALK-ROS1 fusion • EGFR A289V
    |
    Guardant360® CDx
    almost4years
    Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report. (PubMed, Medicine (Baltimore))
    This case report demonstrates that EGFR-ZNF880 fusion and EGFR E114K mutations may contribute or lead to the formation of a special HER2 dimer, which is rapidly resistant to lapatinib but sensitive to pyrotinib. Of note, this is the first report that such a new fusion has been found.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • EGFR mutation • HER-2 overexpression • HER-2 amplification • EGFR positive • EGFR E114K
    |
    Herceptin (trastuzumab) • lapatinib • Irene (pyrotinib)